A High Throughput Protein Formulation Platform: Case Study of Salmon Calcitonin by Capelle, Martinus et al.
Research Paper
A High Throughput Protein Formulation Platform: Case Study of Salmon
Calcitonin
Martinus A. H. Capelle,1 Robert Gurny,1 and Tudor Arvinte1,2
Received April 4, 2008; accepted June 10, 2008; published online July 4, 2008
Purpose. The feasibility of using high throughput spectroscopy for characterization and selection of
physically stable protein formulations was studied.
Materials and Methods. A hundred aqueous formulations of salmon calcitonin (sCT) were prepared
using 20 buffer compositions. The solutions had pH values between 2.5 and 10.5. The stability of the sCT
formulations was analyzed over 1 week by the following assays: (1) protein concentration, (2) volume
control by measuring pathlength, (3) turbidity (absorbance at 350 nm), (4) intrinsic tyrosine ﬂuorescence,
(5) 1-anilino-naphthalene-8-sulfonate (ANS) ﬂuorescence, (6) Nile Red ﬂuorescence. Addition of the
dyes (Nile Red and ANS) was used to study protein conformational changes.
Results. After 1 day, 27 out of the 100 formulations of salmon calcitonin were stable. After 7 days, 12
stable sCT formulations remained. The best salmon calcitonin formulation was in 10 mM sodium acetate
buffer with pH values between 3.5 and 5.5.
Conclusions. The ﬁndings are in accordance with the sCT formulations that were patented and used
commercially. This can be considered as a proof of concept for the high throughput protein formulation
platform.
KEY WORDS: high throughput screening; protein formulation; salmon calcitonin; spectroscopy;
stability.
INTRODUCTION
Calcitonin is a naturally occurring polypeptide hormone
involved in the regulation of calcium and bone metabolism.
Calcitonin is produced in parafollicular cells of the human thyroid
gland (1). In patients with osteoporosis, calcitonin is used to
increase the bone density, prevent bone loss and fractures. In
addition, calcitonin reduces acute pain due to osteolytic fractures,
vertebral crush fractures, and osteolytic bone metastasis (2).
Clinically, calcitonin is indicated for the treatment of postmen-
opausal osteoporosis and Paget’s disease of the bone, either
alone or in combination with other drugs. Calcitonin is only
indicated for women who are at least 5 years beyond meno-
pause, or for women who cannot take alternative medication (3).
Commercially, salmon calcitonin (sCT) is produced synthet-
ically or by using recombinant DNA techniques. The ﬁrst salmon
calcitonin product (Calcimar®) was approved in 1975 by the
Food and Drug Administration (FDA). A human calcitonin
product (Cibacalcin®) was approved by the FDA in 1986.
Salmon calcitonin consists of 32 amino acids and differs from
human calcitonin by 13 residues. At present, in the USA,
several salmon calcitonin formulations are approved for
parenteral (50–100 IU daily, preferably by subcutaneous or
intramuscular injection) or nasal (200 IU daily) administration.
A list of the marketed salmon calcitonin drug products,
approval date, manufacturers, route of administration and
excipients is given in Table I. The speciﬁc activity of sCT was
deﬁned as having 6,000 IU/mg in the Third International
Standard by the World Health Organization (4). The
commercial formulations contain either 200 (injection) or
2,200 IU/ml (multi-dose nasal spray), which corresponds to
sCT concentrations of 0.033 and 0.37 mg/ml, respectively. sCT is
formulated with an acetate buffer (sCT international standard,
Calcimar®, Miacalcin® for injection, Forcaltonin®), hydrochloric
acid (Miacalcin nasal spray) or citric acid (Fortical®).
By 2009, about $10 billion worth of biopharmaceuticals
will have lost patent protection (5). New protein formulations
that are better or bioequivalent to existing protein drugs can
be marketed as ‘biogenerics’ after the patent has expired. An
increase in ‘biogenerics’ and improved biopharmaceutical
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formulations, supergenerics (6), can be expected which would
beneﬁt from a fast drug development and formulation
screening platform. In order to achieve these goals a high
throughput formulation (HTF) platform was developed. The
HTF platform was based on an advanced liquid handling
system and a UV absorbance/ﬂuorescence microplate reader
to study the physical and chemical stability of proteins and
peptides. The HTF platform can help in selecting protein
stabilizing excipients for further protein formulation optimi-
zation. The use of multi-well plates allows the formulation
scientist to screen for a variety of parameters, excipients and
conditions using a relatively small amount of protein. As a
proof of concept of the HTF platform, the sCT stability in 100
buffer solutions was characterized. The buffer solutions,
prepared from 20 buffer types, have pH values between 2.5
and 10.5, and were selected based on their chemical diversity.
MATERIALS AND METHODS
Materials
The chemicals required for preparing the buffer solutions,
and the dyes 1-anilino-naphthalene-8-sulfonate (ANS) and Nile
Red, were provided by Sigma-Aldrich (Sigma-Aldrich Chemie
GmbH, Buchs, Switzerland). The 20 10 mM buffer solutions
(Tables II and III) consisted of: (1) glycine–hydrochloric acid,
(2) citric acid–sodium citrate, (3) citric acid–sodium phosphate
dibasic, (4) potassium phthalate–sodium hydroxide, (5) succinic
acid–sodium hydroxide, (6) ammonium acetate–acetic acid, (7)
histidine–hydrochloric acid, (8) sodium acetate–acetic acid, (9)
β,β′-dimethyl glutaric acid–sodium hydroxide, (10) Tris
(hydroxymethyl)aminomethane–maleate, (11) sodium phos-
phate monobasic–sodium phosphate dibasic, (12) N-(2-acet-
amido)iminodiacetic acid (=ADA)–hydrochloric acid, (13)
citric acid–potassium phosphate dibasic, (14) 3-(N-morpho-
lino)propanesulfonic acid (=MOPS)–potassium hydroxide, (15)
4-(2-hydroxyethyl)-1-piperazine-1-ethanesulfonic acid
(=HEPES)–sodium hydroxide, (16) N-[tris(hydroxymethyl)
methyl]-2-aminoethanesulfonic acid (=TES)–hydrochloric acid,
(17) Tris(hydroxymethyl)aminomethane–hydrochloric acid,
(18) glycine–sodium hydroxide, (19) 3-(cyclohexylamino)-2-
hydroxy-1-propanesulfonic acid (=CAPSO)–sodium hydrox-
ide, (20) sodium carbonate–sodium bicarbonate.
The salmon calcitonin was obtained from Novartis
(Novartis AG, Basel, Switzerland). UV transparent 96-well
Costar® (no. 3635) Corning (Corning Inc., New York, NY,
USA) microplates were supplied by Vitaris (Vitaris SA, Baar,
Switzerland). UV-Vis transparent and pressure sensitive
Greiner VIEWseals™ (Greiner Bio-One GmbH,
Frickenhausen, Germany) were acquired from Huber & Co.
AG (Reinach, Switzerland). Sterile and single wrapped
polystyrene reservoirs with 12 channels (no. 330.12.9) from
Socorex (Socorex Isba S.A., Ecublens, Switzerland)
contained in total 40 ml and were supplied by Milian
(Milian S.A., Geneva, Switzerland). A Millipore (Millipore
Corp., Bedford, Massachusetts) ﬁltration system, comprised
of a vacuum driven disposable bottle top (Stericup™) with
0.22 μm Durapore™ ﬁlter and a presterilized receiver ﬂask
(Steritop™), was used for the ﬁltration of all non-protein
solutions.
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119High Throughput Formulation of Salmon Calcitonin
Preparation of Protein Formulations
A stock solution of 8.0 mg/ml salmon calcitonin in
puriﬁed MilliQ™ Millipore water was freshly prepared. A
hundred 40 mM buffer solutions with pH values between 2.5
and 10.5 (Table II) were prepared using sterile ﬁltered 0.20 M
buffer solutions. The stability of salmon calcitonin was tested
at a concentration of 2.0 mg/ml. This concentration is higher
than the 0.033 and 0.37 mg/ml sCT concentrations that are
used in the marketed sCT drug products. Previous work
showed that with an increase in calcitonin concentration a
decrease in ﬁbrillation time was determined (7). It was
assumed that at a 2.0 mg/ml sCT concentration during a
reasonable amount of time the different aggregation proper-
ties would be distinguishable.
The sCT formulations were prepared in 96-well plates
with a Sciclone ALH500 liquid handling station from Caliper
Life Sciences (Hopkinton, USA). The sample preparation
protocol using the liquid handling station was composed of
the following steps: (1) 100 or 98 μl (if a dye was added) of
water was dispensed using the bulk tool, (2) 50 μl of buffer
was pipetted using the Z-8 liquid handling device with
disposable tips, (3) 50 μl of sCT solution was added, similar
to the dispensing of the buffer solutions, (4) 2 μl of a dye,
0.20 mM ANS or 0.10 mM Nile Red, was simultaneously
added to all 96 wells using a low-volume 96-canula array. The
Table II. The Table Summarizes the Results of the Turbidity, ANS and Nile Red Fluorescence Assays After 1 Day
10mM Buffers pH
2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0 10.5
1 Glycine – Hydrochloric acid
U N U N U NA A A
2 Citric acid – Sodium citrate
U N U N U N U N U N U N U NA A A A A A A
3 Citric acid – Sodium phosphate dibasic
U N U N U N U N U N U N U N U N U N U NA A A A A A A A A A
4 Citric acid – Potassium phosphate dibasic
U N U N U N U N U N U N U N U N U NA A A A A A A A A
5 β,β'-Dimethylglutaric acid – Sodium hydroxide
U N U N U N U N U N U N U N U N U NA A A A A A A A A
6 Acetic acid – Sodium acetate 
U N U N U N U N U NA A A A A
7 Potassium phthalate – Sodium hydroxide
U N U N U N U N U NA A A A A
8 Succinic acid – Sodium hydroxide
U N U N U N U N U NA A A A A
9 Acetic acid – Ammonium acetate
U N U N U N U N U NA A A A A
10 Histidine – Hydrochloric acid
U N U N U N U N U NA A A A A
11 Tris – Maleate
U N U N U N U N U N U NA A A A A A
12 Sodium phosphate monobasic – Sodium phosphate dibasic
U N U N U N U N U NA A A A A
13 ADA – Hydrochloric acid
U N U N U NA A A
14 MOPS – Potassium hydroxide
U N U N U NA A A
15 HEPES – Sodiumhydroxide
U N U N U NA A A
16 TES – Hydrochloric acid
U N U N U NA A A
17 Tris – Hydrochloric acid
U N U N U N U NA A A A
18 Glycine – Sodium hydroxide
U N U N U N U NA A A A
19 CAPSO – Sodium hydroxide
U N U N U NA A A
20 Sodium carbonate – Sodium bicarbonate
U N U N U NA A A
The pH values between pH 2.5 and 10.5, with 0.5 pH unit intervals, are highlighted for the 20 buffer solutions used. Each assay was assigned a
U, A, N which represents the UV turbidity assay, ANS ﬂuorescence emission and Nile Red ﬂuorescence emission, respectively. The samples
found stable with the respective assays have a white background and unstable a grey background.
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100 test formulations were composed of 2.0 mg/ml sCT in
10 mM buffer and were prepared in three variants; with
50 μM ANS, with 1 μM Nile Red and with neither. Each 96-
well plate contained 20 sCT formulations (each formulation
in quadruplicate), four sCT samples in water, ten buffer
control solutions, one puriﬁed MilliQ water and one empty
well (an example of a prepared plate is given in Fig. 2A). If
2 μl dye (ANS or Nile Red) was added to the microplate, 2 μl
less water was used. The control solutions included all buffer
types. The outer columns, 1 and 12, contained no sCT in
buffer since in these columns evaporation is more likely to
occur (8). For each sCT formulation three microplates were
prepared and analyzed, making a total of 15 UV transparent
Corning Costar® 96-well plates: sCT in buffers, sCT in buffers
with ANS and sCT in buffers with Nile Red. After sample
preparations, the plates were sealed with a Greiner
VIEWseal™ and incubated at 25°C in the dark during 7 days.
High Throughput Spectroscopic Analysis
sCT is a polypeptide hormone with a molecular weight of
3,600 Da and contains 32 amino acids, one of which is the
ﬂuorophore tyrosine. The sCT ﬂuorescence emission and
absorbance was measured with a Tecan (Tecan Group Ltd.,
Table III. The results of the tyrosine ﬂuorescence, ANS ﬂuorescence, Nile Red ﬂuorescence and turbidity assays 7 days after preparation are
summarized
10mM  Buffers pH
2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0 10.5
1 Glycine – Hydrochloric acid
U T U T U T
A N A N A N
2 Citric acid – Sodium citrate
U T U T U T U T U T U T U T
A N A N A N A N A N A N A N
3 Citric acid – Sodium phosphate dibasic
U T U T U T U T U T U T U T U T U T U T
A N A N A N A N A N A N A N A N A N A N
4 Citric acid – Potassium phosphate dibasic
U T U T U T U T U T U T U T U T U T
A N A N A N A N A N A N A N A N A N
5 β,β'-Dimethylglutaric acid – Sodium hydroxide
U T U T U T U T U T U T U T U T U T
A N A N A N A N A N A N A N A N A N
6 Acetic acid –Sodium acetate 
U T U T U T U T U T
A N A N A N A N A N
7 Potassium phthalate – Sodium hydroxide
U T U T U T U T U T
A N A N A N A N A N
8 Succinic acid – Sodium hydroxide
U T U T U T U T U T
A N A N A N A N A N
9 Acetic acid – Ammonium acetate
U T U T U T U T U T
A N A N A N A N A N
10 Histidine – Hydrochloric acid
U T U T U T U T U T
A N A N A N A N A N
11 Tris – Maleate
U T U T U T U T U T U T
A N A N A N A N A N A N
12 Sodium phosphate monobasic – Sodium phosphate dibasic
U T U T U T U T U T
A N A N A N A N A N
13 ADA – Hydrochloric acid
U T U T U T
A N A N A N
14 MOPS – Potassium hydroxide
U T U T U T
A N A N A N
15 HEPES – Sodium hydroxide
U T U T U T
A N A N A N
16 TES – Hydrochloric acid
U T U T U T
A N A N A N
17 Tris – Hydrochloric acid
U T U T U T U T
A N A N A N A N
18 Glycine – Sodium hydroxide
U T U T U T U T
A N A N A N A N
19 CAPSO – Sodium hydroxide
U T U T U T
A N A N A N
20 Sodium carbonate – Sodium bicarbonate
U T U T U T
A N A N A N
Each assay was assigned a U, A, N, T which represents the UV turbidity assay, ANS emission, Nile Red emission and tyrosine emission,
respectively. The samples found stable with the respective assays have a white background and unstable a grey background. The selected stable
sCT formulations complied with all four assays.
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Männedorf, Switzerland) Saﬁre™ microplate reader. The
ﬂuorescence was measured using the bottom optics. The
ﬂuorescence emission of tyrosine was determined between
295 and 400 nm. Excitation was at 274 nm using bandwidths
for both excitation and emission of 7.5 nm. The sCT
formulations plus ANS were excited at 378 nm and the
emission was monitored between 460 and 520 nm (examples
shown in Fig. 3A and B). The ﬂuorescence emission of Nile
Red in the presence of sCT was studied between 610 and
670 nm after excitation at 575 nm (examples shown in Fig. 3A
and B). The ﬂuorescence emission of ANS and Nile Red was
analyzed with two different settings, a high and low detection
sensitivity in order to characterize both strong and weak
interactions between the dyes and sCT. The turbidity of sCT
formulations was measured by studying the absorbance at
350 nm (9). The volume or pathlength was controlled by
monitoring the absorbance of water at 975 nm (10). The
concentration of sCT was calculated and the sample prepara-
tion controlled by measuring the UV absorbance at 274 nm
(11). The ﬂuorescence and absorbance was measured at
day 0, 1 and 7. The data output of the XFluor® software of
the Tecan Saﬁre™ microplate reader is in Microsoft®
Excel™. Visual basic macros were developed by the authors
to enable high throughput data analysis.
RESULTS
Spectroscopy
The physical stability of 2.0 mg/ml sCTwas studied in 100
buffer solutions. One of the selection criteria for a stable sCT
formulation is to have an absorbance value below 0.075 at
350 nm. All sCT formulations had absorbance values at
350 nm between 0.04 and 0.06 directly after sample prepara-
tion as well as after 1 day, which were similar to the
absorbance values of the control solutions. Many sCT
formulations at neutral pH values became turbid after 7 days,
in contrast to sCT formulations at acidic and basic pH values.
Some sCT formulations aggregated and formed different
structures, such as gels with varying amount of transparency,
white clumps or dots. In some cases a formulation contained
protein aggregates that were attached to the sides of wells.
Since the absorbance measurement is done in the center of
the well, no increase in absorbance signal was detected. A
visual inspection of all wells was performed to check for the
presence of small aggregates.
The intrinsic tyrosine ﬂuorescence decreased between
day 0 and 1 from about 34,000 (relative ﬂuorescence units) to
about 24,000 RFU (see Supplementary Fig. 1). This effect was
attributed to an increase in the solution temperature between
day 0 and 1. The sCT formulations were prepared with buffer
solutions that were stored at 4°C. The sCT formulations at
pH values above 9 showed a decrease in intrinsic ﬂuores-
cence intensities, caused by the lower absorbance energy of
tyrosine due to deprotonation. The lower ﬂuorescence
intensities observed in potassium phthalate and Tris–maleate
buffer are ascribed to the UV absorbance of these buffer
solutions. The sCT formulations with a less than 6%
increase or decrease in tyrosine ﬂuorescence intensity
between day 1 and 7 were considered stable. Changes in
sCT stability were better distinguished, compared to the
intrinsic tyrosine assay, after addition of ANS or Nile Red.
Only sCT in glycine–HCl pH 3.5 had a strong deviation in
intrinsic ﬂuorescence, with no increased ANS or Nile Red
ﬂuorescence.
The ANS ﬂuorescence emission spectra were analyzed
for each salmon calcitonin formulation. The maximum
ﬂuorescence emission of ANS was found between 480 and
490 nm. In contrast to the Nile Red ﬂuorescence emission,
the ANS maximum ﬂuorescence emission did not shift when
bound to the salmon calcitonin. Therefore, the average ANS
emission at 485 nm was used for the sCT formulation
evaluation (see electronic supplementary material). The
measured ANS intensities differed with pH and buffer type,
indicating different afﬁnities of ANS towards the formed
salmon calcitonin structures. The highest ANS ﬂuorescence
intensities were observed between pH 5 and 8.
In some formulations, binding of Nile Red to salmon
calcitonin resulted in a blue shift in the ﬂuorescence emission
maxima from about 645 to about 620 nm and with a
respective increase in ﬂuorescence intensity of ~150 to
55,000 RFU (Fig. 1). Nile Red emission spectra of 20 sCT
formulations measured after 1 day in a 96-well plate were
recorded with a high sensitivity and are shown in Fig. 2B. The
samples in the corresponding 96-well plate are shown in
Fig. 2A. Measurements using high sensitivity settings are
useful for fast screening of sCT formulations. However, they
do not always offer detailed information on the maximum
emission wavelength. Flattening of some of the ﬂuorescence
emission curves (Fig. 2B) was caused by saturation of the
detector. The maximum emission intensities with corre-
sponding wavelengths were automatically extracted from the
Nile Red emission spectra recorded with low sensitivity
settings. A three-dimensional representation of the emission
wavelength maxima and corresponding ﬂuorescence intensi-
ties of sCT in a 100 buffer solutions, measured 7 days after
preparation, is shown in Fig. 1. The sCT formulations with
Nile Red ﬂuorescence emission maxima higher than 630 nm
and average intensities lower than 300 were considered stable
according to the Nile Red assay. The intensity of 300
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Fig. 1. The Nile Red ﬂuorescence after 7 days in 100 sCT
formulations is shown. The black values are in three-dimensional
space. Binding of Nile Red to sCT resulted in a blue shift from 645 to
620 nm and a ﬂuorescence increase of 150 to 55,000. The stable
formulations are encircled.
122 Capelle, Gurny, and Arvinte
corresponds to twice the average value of Nile Red in
presence of the control solutions. Shifts in the emission
maxima of Nile Red greater than 15 nm are signiﬁcant.
Therefore a limit of 630 nm for the emission maximum of
Nile Red was used as one of the selection criteria for
obtaining stable sCT formulations.
Two buffer solutions, in which the salmon calcitonin was
found stable and unstable, are sodium acetate and sodium
citrate. The average of the four endpoint measurements plus
the ANS and Nile Red ﬂuorescence spectra of the four
replicates per formulation are shown in Fig. 3A and B. An
increase in the extrinsic ﬂuorescence intensity is an indication
of protein instability, such as aggregation. After 7 days,
salmon calcitonin in sodium citrate pH 3.0 and 3.5 had an
increased turbidity monitored at 350 nm (Fig. 3A). However,
no change was observed in any of the three ﬂuorescence
assays (Fig. 3A). No change in ANS ﬂuorescence was
observed for sCT in sodium citrate pH 4.0, although an
increased Nile Red ﬂuorescence and increased absorbance at
350 nm were measured (Fig. 3A). All sodium acetate sCT
formulations with pH values of 3.5 to 5.5 were found stable
according to all four assays (Fig. 3B). The Nile Red
ﬂuorescence intensity decreased in time, which was also
observed for other stable sCT formulations. This decrease
can be related to the adsorption of Nile Red to the walls of
the 96-well plate.
A summary of the ANS and Nile Red ﬂuorescence and
absorbance at 350 nm after 1 day of sample preparation is
given in Table II. After 1 day, an increased ANS and Nile
Red ﬂuorescence was observed for most of the sCT
formulations with pH values higher than 4.5. The results
after 7 days, regarding the turbidity at 350 nm, intrinsic
tyrosine ﬂuorescence, ANS ﬂuorescence and Nile Red
ﬂuorescence assays are summarized in Table III. The
absorbance spectra, tyrosine ﬂuorescence, ANS ﬂuorescence
and Nile Red ﬂuorescence emission spectra were analyzed for
each of the sCT formulations and the average results are
shown in electronically available supplementary material.
The overview Tables II and III and the following
examples highlight the necessity of using several complemen-
Fig. 2. A, B 20 sCT formulations (columns 2 to 11) and the respective controls (columns 1 and 12) are given
on the top, in A. Asterisk is an example of the description of the well (sCT control in water) with the
corresponding ﬂuorescence intensity. Four replicates per formulation were prepared. Nile Red emission
spectra after 7 days, using high sensitivity settings, are shown on the bottom, in B. The sCT in sodium citrate
and sodium citrate phosphate pH 3.0 and 3.5 and in glycine pH 2.5 to 3.5 remained stable.
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tary methods for the selection of stable protein formulations.
Salmon calcitonin in glycine–HCl buffer had after 7 days no
increase in ANS and Nile Red ﬂuorescence intensity.
However, an increased turbidity (pH 2.5, 3.0 and 3.5) and
variation in the intrinsic tyrosine ﬂuorescence (pH 3.5) were
measured. Salmon calcitonin was more stable at low pH
values in potassium citrate phosphate than in sodium citrate
phosphate. Analysis of the individual ANS ﬂuorescence
spectra at pH 3.0 revealed that the strong ANS ﬂuorescence
is caused by one out of four replicates. A strong variation in
extrinsic ﬂuorescence intensities was observed with sCT in
potassium citrate phosphate, sodium citrate phosphate and
sodium citrate solutions with pH values lower than 6. This is
probably due to the still on-going aggregation of tree or
branched-like structures that formed in time a protein gel. The
sCT formulations in the same buffer solutions at pH values of 6
and higher formed, in less than a week, turbid homogeneous
gels. These observations were visible with the eye.
Salmon calcitonin was found to be unstable at pH values
between 4.0 and 6.0 in sodium succinate, because of an
increased turbidity at 350 nm. However, the ANS and Nile
Red ﬂuorescence intensities remained low for pH 4.0 and 4.5
(Table III and online available supplementary material).
Salmon calcitonin formulations in ammonium acetate buffer
pH 5.0 and higher had an increased ANS ﬂuorescence, which
was not observed for sCT in sodium acetate (Table III and
Fig. 3). The sCT aggregated in histidine solutions according to
the four assays at all measured pH values. The use of sodium
phosphate resulted in increased absorbance values and changes
in intrinsic and extrinsic ﬂuorescence intensities of sCT.
Sodium citrate
UV (350nm) F (Tyr) F (ANS) F (Nile Red)
2 3 4 5 6 7 8 9 10 11
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
z
pH
2 3 4 5 6 7 8 9 10 11
0
5000
10000
15000
20000
25000
30000
35000
40000
pH
2 3 4 5 6 7 8 9 10 11
0
500
1000
1500
2000
10000
20000
30000
40000
50000
pH
2 3 4 5 6 7 8 9 10 11
0
500
1000
1500
2000
10000
20000
30000
40000
50000
pH
Day 0 Day 1 Day 7
   Legend
F 
(A
NS
) 
460 470 480 490 500 510 520
0
200
400
600
800
1000
1200
Wavelength (nm)
460 470 480 490 500 510 520
0
2000
4000
6000
8000
10000
Wavelength (nm)
460 470 480 490 500 510 520
0
5000
10000
15000
20000
25000
30000
35000
40000
Wavelength (nm)  
F 
(N
ile
 R
ed
)
610 620 630 640 650 660 670
0
200
400
600
800
1000
1200
1400
1600
1800
2000
Wavelength (nm)
610 620 630 640 650 660 670
0
2000
4000
6000
8000
10000
Wavelength (nm)
610 620 630 640 650 660 670
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
50000
Wavelength (nm)
  pH 3.0
  pH 3.5
 pH 4.0
  pH 4.5
  pH 5.0
  pH 5.5
  pH 6.0
Fig. 3. A The UV absorbance at 350 nm, tyrosine intrinsic ﬂuorescence emission at 308 nm, ANS emission intensity at 485 nm and Nile Red
maximum ﬂuorescence intensity measured after 0 (filled circles), 1 (empty circles) and 7 days (x marks) are given. The ANS and Nile Red
ﬂuorescence spectra of sCT in sodium citrate after 0, 1 and 7 days are shown of the four replicates per pH value. The ﬂuorescence intensity
axes were optimized for each day. The sCTwas unstable in sodium citrate with pH between 4 and 6. B The UVabsorbance at 350 nm, tyrosine
intrinsic ﬂuorescence emission at 308 nm, ANS emission intensity at 485 nm and Nile Red maximum ﬂuorescence intensity measured after 0
(filled circles), 1 (empty circles) and 7 days (x marks) are given. The ANS and Nile Red ﬂuorescence emission of sCT in sodium acetate after 0,
1 and 7 days remained low, indicating no binding of the dyes to the protein occurred. A decrease in Nile Red ﬂuorescence after 1 day was
observed. The sCT was found to be stable in sodium acetate with pH values between 3.5 and 5.5 during at least 1 week.
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After 7 days, no suitable buffer solutions were found for
sCT that had pH values of 6.0 or more. The salmon calcitonin
turbidity at 350 nm in buffer solutions 13 to 20 (Table III) was
low, except for ADA pH 6.0, HEPES pH 7.0 and sodium
carbonate pH 10.5, where slightly increased turbidities were
measured. The ANS ﬂuorescence increased in all these
solutions, where the Nile Red ﬂuorescence intensities
remained low for the following formulations: MOPS–KOH
pH 6.5, HEPES pH 7.0 and 7.5, glycine–NaOH pH 9.0.
Salmon calcitonin remained stable for 1 day at pH values
similar to the physiological pH in the following buffer
solutions: MOPS–KOH pH 6.5 and 7.5, HEPES pH 7.5,
TES pH 7.0.
DISCUSSION
The proof of concept of a high throughput protein
formulation platform is presented in this paper using salmon
calcitonin as a model protein. The sCT physical stability was
studied in 100 formulations with the following assays: (1)
protein concentration, (2) volume control by measuring
pathlength, (3) turbidity (absorbance at 350 nm), (4) intrinsic
tyrosine ﬂuorescence, (5) ANS ﬂuorescence, (6) Nile Red
ﬂuorescence. The intrinsic tyrosine ﬂuorescence assay led to
the discarding of about 15 formulations that were turbid by
eye. In the case of salmon calcitonin, intrinsic ﬂuorescence is
less sensitive to detect aggregation as extrinsic (1,8-ANS or
Nile Red) ﬂuorescence. Assays to control for the dispensed
volume, possible evaporation and protein concentration of
the samples were performed. In our experiments, no evapo-
ration occurred during the 7 days of storage, although a
reduction in pathlength was observed for sCT formulations
that formed a compact and hard gel.
The described high throughput platform can be enlarged
with techniques to facilitate accelerated stability testing or
other complementary methods to characterize the physical
(e.g. ﬂuorescence anisotropy, ﬂuorescence lifetime and neph-
elometry) and chemical (e.g. capillary electrophoresis, liquid
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chromatography and mass spectrometry) stability (12). The
combination of high throughput turbidity measurements with
accelerated stability tests, by means of mechanical stress, was
shown to be useful in protein formulation (13). However,
high throughput turbidity screening of protein solutions often
is hindered by the requirement of high protein concentrations
and the high variation in absorbance signal (14). This
variation can be caused due to the relatively small diameter
(Ø~0.75 mm) of the light beam, which corresponds to less
than 1% of the surface of a 96 well (Ø~9.0 mm), and the
irregular growth of protein aggregates. Measurement at
multiple points inside a well will reduce the variation in the
turbidity signal. However, a more complicated data analysis
and increased measurement time can be expected.
The ﬁbrillation lag time of calcitonin is known to
decrease with an increase in concentration (7, 15, 16).
Aggregated salmon calcitonin formed different structures as
observed by eye, which is reﬂected in the different ﬂuores-
cence and absorbance intensities. The absorbance at 350 nm
was not sensitive enough to detect all forms of sCT
aggregates, in particular at pH values of 7.0–10.5. If the
turbidity assay would have been used as a stand-alone assay,
several unstable sCT formulations would have been selected.
The use of complementary ﬂuorescence assays narrowed
down the selection of stable salmon calcitonin formulations.
The ﬂuorescence of ANS is known to increase after
binding to hydrophobic regions of proteins (17). ANS binds
primarily through electrostatic interactions of the ANS anion
to the cationic groups of the protein (18). The binding of dyes
to proteins that expose hydrophobic surfaces does not always
lead to increased ﬂuorescence intensity. No ﬂuorescence
increase was observed for up to 17 ANS anions that were
bound in acidic pH to lysozyme (18). BSA below pH 5.0 has
as many as 100 ANS binding sites, where 95% of the protein
bound ANS is non ﬂuorescent (18). Similar effects may
explain the low ANS or Nile Red ﬂuorescence intensities of
sCT in glycine–HCl buffer pH 2.5 to 3.5. Another explanation
could be that at acidic pH, ANS is less charged and therefore
it interacts with protein aggregates mainly through hydro-
phobic interactions rather than electrostatic interactions.
Another ANS binding study, together with circular dichroism
and intrinsic ﬂuorescence analysis, characterized the different
conformational states of β-lactamase between pH 2.0 and
12.0 (19). The ANS ﬂuorescence was stable in the entire pH
range, except for a time-dependent increase of ANS ﬂuores-
cence at pH 2.0 (19). In our high throughput study, no ANS
ﬂuorescence intensity increase caused by pH of buffer
solutions was observed. The ANS ﬂuorescence augmented
in all sCT formulations with pH 6.0 or higher. This is
attributed to the binding of ANS to the hydrophobic regions
formed in sCT multimers and aggregates.
The ﬂuorescence of Nile Red is strongly inﬂuenced by
the polarity of its environment. Nile Red can interact with
many proteins, is photostable and can detect the exposure or
formation of hydrophobic surfaces (20, 21). The Nile Red
ﬂuorescence was shown in several studies to be unaffected at
a variety of pH ranges: 4.5–8.5 (20), 6.0–10.0 (22). We
measured a signiﬁcant increase in Nile Red ﬂuorescence
emission in three salmon calcitonin formulations at pH 4.0
(sodium citrate, sodium citrate phosphate and potassium
phthalate) and up to pH 10.5 compared to the control
solutions. These Nile Red ﬂuorescence intensities in the
salmon calcitonin formulations were signiﬁcantly higher than
the Nile Red in the control buffer solutions. The Nile Red
ﬂuorescence intensity in stable sCT formulations decreased
after 1 day, which is caused by slight temperature differences,
as was the case for the intrinsic tyrosine, or by adsorption to
walls of the microplate. Nile Red adsorbed on plastic, glass,
or quartz becomes non-ﬂuorescent (20).
Spiking of protein formulations with the dye prior to
analysis is preferred over the incorporation of the dye in the
protein formulation (21). Dyes might alter the protein
conformation, as it has been previously reported that ANS
induced folding of acid unfolded cytochrome c to the molten
globule state as a result of electrostatic interactions (23). The
ﬂuorescence intensity of the added dyes can be inﬂuenced by
changes in protein conformation or by incubation. Spiking of
the formulation with the dye prior to each analysis time point
can be performed. This is in particular useful when studying
the stability of protein formulations over long time periods
(months to a year) or when the formulations are stored at
higher temperatures. However, we do not recommend spiking
samples with dyes in a high throughput screening study of up
to one month if no interference of the dye with the protein
stability was detected. Nile Red did not change the stability of
salmon calcitonin (21) and the dye was added once at time
zero.
After 1 day of measurement, 27 from a total of 100 sCT
formulations (Table II) were found to be stable according to
the turbidity, ANS and Nile Red ﬂuorescence assays. After
7 days of sample preparation, based on the results of the
turbidity, intrinsic tyrosine ﬂuorescence, ANS ﬂuorescence
and Nile Red ﬂuorescence assays, only 12 sCT formulations
remained stable (Table III). The formulations, with a
complete white background in Table III, are: sodium citrate
phosphate pH 3.0; potassium citrate phosphate pH 3.5 and
4.0; dimethyl glutaric acid pH 3.5, pH 4.0 and 4.5; sodium
acetate pH 3.5, 4.0, 4.5, 5.0 and 5.5; ammonium acetate
pH 4.5. The sodium acetate was the best buffer solution for a
sCT drug formulation, since the protein remained stable at all
measured pH values, even at pH 5.5.
The Forcaltonin®, Miacalcin® and Calcimar® com-
mercial sCT solutions for injection contain sodium acetate
(Table I), which conﬁrms with the results of our high
throughput formulation study. The respective incorporation
of hydrochloric acid and citric acid in Miacalcin® nasal spray
and Fortical® nasal spray is another indication that sCT is
stable in an acidic environment. However, salmon calcitonin
is not generally stable at low pH values (e.g. glycine–HCl
pH 2.5–3.5). The stabilizing effect of sodium acetate on
salmon calcitonin is due both to sodium and acetate, since the
use of sodium citrate and ammonium acetate at pH 5.0 and
5.5 resulted in an increased ANS ﬂuorescence.
The selection of stable protein formulations depends on
the set criteria per assay. These criteria need to be continu-
ously evaluated during data analysis. Data analysis can be a
time-consuming task. For example, the ANS and Nile Red
emission were measured in their emission maxima over a
60 nm range and the intrinsic tyrosine over 40 nm to reduce
measurement time and to facilitate data handling. With these
settings and including the different absorbance assays, about
180,000 data points were acquired per day out of a total of 15
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microplates. Automated determination of average values,
including standard deviations and variations of endpoint
measurements (absorbance or emission value at a single
wavelength) gave an indication about the reproducibility and
can help in ﬁnding wells with variations in e.g. the protein
concentration and volume. Analysis of absorbance and
emission spectra is required before excluding samples (e.g.
individual wells) from the study, as is explained further.
Different graphical representation of data is possible, as can
be seen in Figs. 1, 2, 3 and the electronically available
supplementary material. The ﬂuorescence emission spectra
can either be analyzed with or without the plotting of spectra.
In-house build visual basic macros selected automatically the
maximum intensity values with corresponding wavelengths.
These values changed depending on the interaction of the dye
with the protein. Line graphs or three-dimensional graphs,
such as Fig. 1, help to quickly understand the behavior of the
protein (e.g. ﬂuorescence intensity) in relation to the
parameter tested, which was the case of the pH. Plotting of
96 ﬂuorescence emission spectra per analyzed microplate in
time showed the protein behavior per buffer and in relation
to the position in the plate. Detection of a consequent error in
sample pipetting and thus in concentration can be found,
since in our HTF platform the protein samples are horizon-
tally dispensed in the microplate by eight individual pipettors.
Generally, evaporation starts to occur in the outer columns
and rows of a well plate, which can be detected by visualizing
spectra per plate.
In our high throughput study the average values of four
replicates per sCT formulation were used. In several cases,
one out of these four replicates could have been designated in
the ﬂuorescence assays as an outlier. However, no such
statistical approach was applied and all replicates contributed
to the reported data. In the ANS ﬂuorescence emission
spectra at day 0 of sCT in glycine–HCl pH 3.0, one sample
showed a six times stronger ﬂuorescence intensity than the
other three replicates. After a day, this strong ﬂuorescence
decreased and became similar to the ﬂuorescence of the
replicates. Presence of air bubbles, droplets, or other
technical issues could be the explanation for this increased
value at day 0. Salmon calcitonin in potassium citrate
phosphate buffer pH 3.0 is stable to all but the ANS emission
assay. This is unexpected since sCT in potassium citrate
phosphate pH 3.5 and 4.0 complied with all four assays. One
out of the four replicates of sCT in potassium citrate
phosphate pH 3.0 had a strong ANS ﬂuorescence at day 0,
1 and 7. No experimental reasons could be found to eliminate
this sample, which resulted in salmon calcitonin being not
stable in potassium citrate phosphate buffer pH 3.0. In other
formulations, one out of four sCT samples showed an
increased initial ﬂuorescence or absorbance that continued
to increase in time. The remaining replicates showed, only
after a prolonged time, similar spectroscopic changes caused
by the irregular aggregation formation in some buffers.
Automated data analysis can help pinpoint these outliers.
The assay criteria were established based on the
intensities of the background values and variation in stable
sCT formulations and control solutions. For each assay, the
sCT formulations were awarded a score (white or grey
background), either stable or not according to each assay,
and presented in overview tables (see Tables II and III).
Stable protein formulations can then be selected for further
optimization, analysis or immediate use. We suggest investi-
gating the origin of the changes if the protein formulation is
considered stable with three out of four assays.
With controlled storage conditions (e.g. humidity and
temperature), high throughput analysis can be performed
over more than a week. There are no limitations to the length
of the high throughput screening study. The formulations can
be stored also outside the microplate in for example vials or
deep-well storage plates. At each stability time point, the
formulations can be pipetted (with or without an extrinsic dye)
in a 96-well plate for characterization. A decrease in total
measurement time (e.g. decrease in protein aggregation lag
time) and increase in throughput can be obtained when
combining accelerated stress testing, e.g. shaking or storage at
elevated temperatures, with high throughput spectroscopy (13).
The screening of sCT formulations over a broad pH
range resulted in several leads for further formulation
optimization, one of which included the commercially used
sodium acetate buffer. The HTF platform can be applied for
fast developing stable formulations of other peptides and
proteins. The HTF platform can be used with extrinsic dyes at
low protein concentration (<50 μg/ml) and at high protein
concentration (e.g. 100–300 mg/ml). The analytical methods
have to be adapted to these extreme concentration con-
ditions. Phenomena such as protein binding to walls at low
protein concentration or high viscosity at high protein
concentration have to be taken into account.
It is our opinion that, if enough protein substance is
available, many parameters need to be studied to completely
understand the physical and chemical properties of the drug.
In this endeavor, high throughput screening platforms will
provide a valuable tool to characterize protein formulations.
CONCLUSION
After 1 week, 12 out of 100 salmon calcitonin formula-
tions were found to be stable. The physical stability study was
performed in 96-well plates and the two tested parameters
were buffer type and pH value. The sodium acetate buffer at
pH values of 3.5 to 5.5 was the best candidate for further sCT
formulation optimization. The sCT remained stable according
to the turbidity, intrinsic and extrinsic ﬂuorescence assays. It
should be noted that several commercial sCT formulations
contain a sodium acetate buffer. The leads found using our
novel high throughput methods have already been used or
patented, which validates our approach and can be consid-
ered as a proof of concept for the high throughput protein
formulation platform.
The use of several complementary analytical methods
permits the selection of formulations using carefully selected
assay criteria. We have shown that, in some cases, an increase
in turbidity was observed without an increased ANS or Nile
Red ﬂuorescence. In other formulations, an increase in
ﬂuorescence was detected without an increased turbidity.
Therefore, we recommend measuring the ﬂuorescence of at
least two dyes in combination with turbidity and intrinsic
ﬂuorescence. Growth of protein aggregates at the side of
wells can stay undetected if the measurement is only
performed in the centre of the well. Therefore, determining
turbidity at different positions in the well will result in a
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reduction in the variation of the apparent absorbance. The
intrinsic tyrosine ﬂuorescence was, in the case of salmon
calcitonin, not a decisive factor, and the ﬂuorescence only
changed in strongly aggregated formulations.
Taken together, high throughput spectroscopy is a fast
and versatile method for initial screening of the physical
stability of protein formulations. The well-plate based plat-
form could be enhanced with an accelerated stress testing and
methods to determine chemical stability, e.g. electrophoresis,
HPLC, mass spectrometry.
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